Novel treatment to restore neurological function in patients with Multiple Sclerosis
Medicine
Ref.-No.: 0707-5835-IKF
Technology
Researchers at the Max Planck Institute of Experimental Medicine have identified squalene, a cholesterol-synthesis intermediate, as pharmaceutically active agent for use in the prevention and/or treatment of demyelinating disorders such as multiple sclerosis.
This compound acts as LXR agonist, facilitating the resolution of inflammatory processes and promoting the availability of cholesterol necessary for remyelination.
Oral administration of squalene in relevant mouse models of demyelinating diseases has demonstrated the resolution of inflammation and the promotion of remyelination, with a significant improvement in the clinical score.
Therefore, squalene could serve as a valuable complement to disease-modifying therapies, significantly enhancing their effectiveness and offering new hope to patients affected by Multiple Sclerosis.
Patent Information
International Patent Application No. PCT/EP2020/084338, filed on December 2, 2020.
Opportunity
We are open to research collaborations or license agreements to accelerate the integration of this promising compound into the clinical practice.
PDF Download
- Ref.-No.: 0707-5835-IKF (450.9 KiB)
Contact
Dr. Ingrid Kapser-Fischer
Nutritionist, M.Sc.
Phone: +49 89 / 29 09 19-19
Email:
kapser-fischer@max-planck-innovation.de